BioMarin Pharmaceutical reported $825M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
Agios Pharmaceuticals USD 12.45M 3.75M Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Bayer EUR 10.74B 3B Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
Incyte USD 1.06B 10M Jun/2025
Insmed USD 107.4M 14.58M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
Moderna USD 142M 34M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
PTC Therapeutics USD 178.9M 11.1M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 10.74B 529.51M Jun/2025
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
United Therapeutics USD 798.6M 4.2M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025